Hey there, time traveller!
This article was published 19/11/2013 (955 days ago), so information in it may no longer be current.
Miraculins Inc., a Winnipeg company that makes medical diagnostic equipment, is planning a multi-pronged effort to market the Scout DS non-invasive diabetes screening technology.
The company has announced its intention to pursue a regulatory strategy for a submission to the FDA to gain approval for sale and distribution of the Scout DS in the U.S.
It is also entering into a letter of intent to negotiate the licensing rights for the Scout DS in China.
The company has also re-appointed Pear Healthcare Solutions as the distributor of the Scout DS to the Canadian Pharmacy segment and is facilitating placement of the Scout DS into a major Canadian retail/food pharmacy chain pilot program.
Miraculins has decided to sell Scout DS devices to established distributors in key market segments, which will then subsequently be rented or leased to their network of customers on a weekly, monthly or annual basis.
Use of the Scout DS device requires the additional purchase of proprietary consumable materials that will generate moderate additional revenue per test. Further revenues may be generated through territorial licensing, or through marketing partnerships with corporate brand partners who have an interest in further linking their brands and products with heath and wellness and may involve the payment of upfront, milestone and maintenance fees.